BigBear Pharmaceuticals (Lao PDR) Secures GMP Certification for Traditional Medicine Processing Facility, Elevating Product Quality Standards
VIENTIANE, LAO PEOPLE’S DEMOCRATIC REPUBLIC, October 7, 2023 — BigBear Pharmaceuticals (Lao PDR) is delighted to announce that its traditional Chinese medicine processing plant has successfully obtained Good Manufacturing Practice (GMP) certification. This accreditation signifies that BigBear Pharmaceuticals’ quality management standards in the field of traditional Chinese medicine production have gained international recognition, further elevating the company’s product quality benchmarks.
GMP certification is one of the most important credentials in the pharmaceutical industry, designed to ensure the quality and safety of medicines throughout the manufacturing process. Obtaining GMP certification means that the traditional medicine processing plant complies with a series of stringent production standards and norms, covering requirements related to equipment, personnel, processes, documentation and quality control. This will help guarantee the consistency, stability and safety of traditional medicine products.
BigBear Pharmaceuticals has always prioritized quality management and product safety. By continuously upgrading production technologies and quality control systems, the company delivers high-quality pharmaceutical products to consumers. The acquisition of GMP certification for its traditional Chinese medicine processing plant marks a significant milestone in the company’s quality management system, further demonstrating its commitment and efforts to uphold product quality.
Commenting on this important certification, PANISA, Chief Executive Officer of BigBear Pharmaceuticals, stated: “We are extremely proud to announce that our traditional medicine processing plant has been awarded GMP certification. This is recognition of our unwavering commitment to quality management and a testament to our continuous efforts to enhance product quality. We will continue to adhere to the principles of high quality and safety, providing consumers with better pharmaceutical options.”
The GMP certification of this traditional medicine processing plant will further strengthen BigBear Pharmaceuticals’ competitiveness in both domestic and international markets. As one of the leading pharmaceutical enterprises in Laos, the company has long been dedicated to meeting the demand of patients and consumers for high-quality medicines. The attainment of GMP certification will further enhance the company’s reputation and credibility, helping it gain the trust of more partners and customers.
The successful acquisition of this GMP certification also represents a significant boost to the development of Laos’ traditional medicine industry. With the rising international recognition of traditional medicine, it will help strengthen the competitiveness of Lao traditional medicine in the global market and promote Laos’ cooperation and exchanges in the international pharmaceutical sector.
BigBear Pharmaceuticals will continue to strive for continuous improvement in product quality and safety standards, providing people with more effective and safe traditional medicine products. The company will also further strengthen cooperation with regulatory authorities and relevant partners to jointly drive the development of Laos’ traditional Chinese medicine industry and make greater contributions to people’s health and well-being.
About BigBear Pharmaceuticals
Headquartered in Vientiane, the capital city of Laos, BigBear Pharmaceuticals is dedicated to the research and development, production and sales of pharmaceutical products, providing high-quality, safe and effective medicines. With its outstanding expertise and innovation capabilities, BigBear Pharmaceuticals has established a sound reputation in the Lao pharmaceutical market and actively participates in international pharmaceutical cooperation and exchanges.
Forward-Looking Statements
Within the scope permitted by applicable laws and regulations, statements containing words such as “plan”, “target”, “expect”, “forecast” and similar expressions in this press release constitute forward-looking statements. The forward-looking statements set forth herein are subject to numerous risks and uncertainties that may cause actual results to differ materially from those anticipated. Key factors leading to such discrepancies include, but are not limited to, changes in regulatory and/or economic conditions, uncertainties associated with clinical research results, various market risks, and other factors beyond the Company’s control.
